DNAY Stock Price, Chart, Stats & News
Codex DNA, Inc. (DNAY) does not currently pay a dividend.
DNAY chart
Price history is unavailable
We don't have enough price data for DNAY to draw a chart yet.
Fundamentals
Gross margin | 56.84% |
Operating margin | -181.20% |
Pretax margin | -176.59% |
Net margin | -176.50% |
Effective tax rate | 0.05% |
ROA | -59.52% |
ROE | -70.51% |
D/E | 0.46x |
Interest coverage ratio | 40.85x |
DNAY valuation
P/E | – |
P/S | 1.40x |
P/B | 0.82x |
P/CF | -0.99x |
P/FCF | -0.89x |
P/OCF | -0.99x |
PEG | 0.35x |
EV multiple | -1.02x |
About
Operating in the synthetic biology sector, Codex DNA, Inc. develops, manufactures, and sells advanced instruments, reagents, and complementary services. Its primary customer base comprises pharmaceutical firms and academic laboratories worldwide, though it also extends its offerings to government institutions, contract research organizations, and other synthetic biology companies. The company's innovative product portfolio includes the BioXp system, designed to transform digital DNA sequences into usable synthetic DNA, alongside the intuitive BioXp portal, an online platform facilitating DNA sequence design and assembly into chosen vectors.
Similar securities
Based on sector and market capitalization
